Cryoport, Inc. (CYRX)
Chart Events
Performance Outlook
| Previous Close | 24.10 |
| Open | 23.84 |
| Bid | 23.27 x 1000 |
| Ask | 23.33 x 1100 |
| Day's Range | 23.17 - 24.10 |
| 52 Week Range | 15.63 - 45.36 |
| Volume | |
| Avg. Volume | 474,281 |
| Market Cap | 1.14B |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYRX
Related Research
- CryoPort, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.RatingFair ValueEconomic Moat5 days agoMorningstar
- PR Newswire
Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. Both Cryoport and Syneos Health are world leading solutions companies with deep ex
- PR Newswire
Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 41st Annual Healthcare conference, taking place from January 9 - 12, 2023 in San Francisco, CA. Mr. Shelton will be presenting on Thursday, January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET). Additionally, Mr. Shelton, Robert St
- PR Newswire
Cryoport Reports Results for the Third Quarter 2022
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and nine-month periods ended September 30, 2022.
